U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable

Core Viewpoint - Biofrontera Inc. has successfully challenged the validity of Sun Pharmaceutical Industries, Inc.'s U.S. Patent No. 11,697,028, leading to a decision by the U.S. Patent Trial and Appeal Board that all challenged claims of the patent are unpatentable [1][2]. Group 1: Legal Proceedings - In June 2024, Sun Pharma initiated legal proceedings against Biofrontera for alleged infringement of the '028 Patent and U.S. Patent No. 11,446,512 [2]. - Biofrontera responded by filing petitions for Inter Partes Review with the Board, which has now ruled in favor of Biofrontera regarding the '028 Patent [2][3]. - Sun Pharma retains the right to appeal the Board's decision to the United States Court of Appeals for the Federal Circuit [3]. Group 2: Company Focus and Products - Biofrontera specializes in photodynamic therapy (PDT) for dermatological conditions, particularly through its drug-device combination Ameluz and the RhodoLED lamp series [4]. - The company aims to expand its clinical research and development efforts to treat non-melanoma skin cancers and moderate-to-severe acne [4].